A detailed history of Charles Schwab Investment Management Inc transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 1,184,609 shares of TGTX stock, worth $37.6 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,184,609
Previous 1,176,670 0.67%
Holding current value
$37.6 Million
Previous $20.9 Million 32.37%
% of portfolio
0.01%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$17.21 - $25.28 $136,630 - $200,697
7,939 Added 0.67%
1,184,609 $27.7 Million
Q2 2024

Aug 12, 2024

BUY
$13.32 - $19.19 $414,265 - $596,828
31,101 Added 2.71%
1,176,670 $20.9 Million
Q1 2024

May 08, 2024

BUY
$13.02 - $21.3 $178,022 - $291,234
13,673 Added 1.21%
1,145,569 $17.4 Million
Q4 2023

Feb 06, 2024

BUY
$6.68 - $18.81 $128,349 - $361,415
19,214 Added 1.73%
1,131,896 $19.3 Million
Q3 2023

Nov 08, 2023

BUY
$8.36 - $26.5 $266,449 - $844,608
31,872 Added 2.95%
1,112,682 $9.3 Million
Q2 2023

Aug 09, 2023

BUY
$15.48 - $35.0 $542,697 - $1.23 Million
35,058 Added 3.35%
1,080,810 $26.8 Million
Q1 2023

May 11, 2023

BUY
$10.23 - $19.34 $280,762 - $530,786
27,445 Added 2.7%
1,045,752 $15.7 Million
Q4 2022

Feb 13, 2023

BUY
$5.01 - $11.83 $137,519 - $324,721
27,449 Added 2.77%
1,018,307 $12 Million
Q3 2022

Nov 14, 2022

BUY
$4.57 - $8.4 $224,780 - $413,162
49,186 Added 5.22%
990,858 $5.87 Million
Q2 2022

Aug 15, 2022

SELL
$3.74 - $10.66 $51,428 - $146,585
-13,751 Reduced 1.44%
941,672 $4 Million
Q1 2022

May 13, 2022

BUY
$7.81 - $20.45 $132,996 - $348,243
17,029 Added 1.81%
955,423 $9.09 Million
Q4 2021

Feb 11, 2022

BUY
$15.2 - $35.51 $363,690 - $849,647
23,927 Added 2.62%
938,394 $17.8 Million
Q3 2021

Nov 16, 2021

BUY
$21.78 - $40.45 $999,375 - $1.86 Million
45,885 Added 5.28%
914,467 $30.4 Million
Q2 2021

Aug 16, 2021

BUY
$32.5 - $48.96 $897,617 - $1.35 Million
27,619 Added 3.28%
868,582 $33.7 Million
Q1 2021

May 17, 2021

BUY
$41.61 - $54.3 $4.73 Million - $6.18 Million
113,794 Added 15.65%
840,963 $40.5 Million
Q4 2020

Feb 16, 2021

BUY
$25.27 - $54.9 $862,111 - $1.87 Million
34,116 Added 4.92%
727,169 $37.8 Million
Q3 2020

Nov 13, 2020

BUY
$18.49 - $27.24 $820,863 - $1.21 Million
44,395 Added 6.84%
693,053 $18.5 Million
Q2 2020

Aug 14, 2020

BUY
$8.9 - $21.84 $860,825 - $2.11 Million
96,722 Added 17.52%
648,658 $12.6 Million
Q1 2020

May 15, 2020

BUY
$7.14 - $15.99 $277,660 - $621,819
38,888 Added 7.58%
551,936 $5.43 Million
Q4 2019

Feb 07, 2020

BUY
$5.1 - $11.2 $231,534 - $508,468
45,399 Added 9.71%
513,048 $5.7 Million
Q3 2019

Nov 08, 2019

BUY
$5.38 - $8.99 $167,942 - $280,631
31,216 Added 7.15%
467,649 $2.63 Million
Q2 2019

Aug 09, 2019

BUY
$6.27 - $8.65 $298,357 - $411,610
47,585 Added 12.24%
436,433 $3.78 Million
Q1 2019

May 14, 2019

BUY
$4.02 - $8.04 $163,348 - $326,697
40,634 Added 11.67%
388,848 $3.13 Million
Q4 2018

Feb 14, 2019

BUY
$3.44 - $5.76 $63,870 - $106,945
18,567 Added 5.63%
348,214 $1.43 Million
Q3 2018

Nov 13, 2018

BUY
$5.15 - $14.0 $81,859 - $222,530
15,895 Added 5.07%
329,647 $1.85 Million
Q2 2018

Aug 08, 2018

BUY
$12.5 - $15.0 $569,725 - $683,670
45,578 Added 17.0%
313,752 $4.13 Million
Q1 2018

May 07, 2018

BUY
$8.7 - $16.8 $10,474 - $20,227
1,204 Added 0.45%
268,174 $3.81 Million
Q4 2017

Jan 17, 2018

BUY
$7.35 - $12.3 $172,614 - $288,865
23,485 Added 9.65%
266,970 $2.19 Million
Q3 2017

Nov 13, 2017

BUY
$10.0 - $12.7 $2.43 Million - $3.09 Million
243,485
243,485 $2.89 Million

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $4.61B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.